Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted long-read sequencing enables comprehensive analysis of the genetic and epigenetic landscape of inherited myopathies.

Nature communications·2026
Same author

COVID-19 Vaccine Reactogenicity Marks an Innate Inflammatory Response Associated With HLA Variation and Enhanced Protection.

Research square·2026
Same author

DNA methylation reprogramming in marsupial embryos is restricted to the extraembryonic lineage.

Nature communications·2026
Same author

Optical mapping reveals a higher level of large-scale structural variants in a family with paternally transmitted myotonic dystrophy and independent Parkinson's disease.

The Journal of pathology·2026
Same author

Cardiomyopathy and Sudden Cardiac Death as a Rare Presentation of Mucolipidosis Type III in a Family With Compound Heterozygous Variants in <i>GNPTAB</i>.

Circulation. Genomic and precision medicine·2026
Same author

SARS-CoV-2 Spike Protein's Structural Dynamics Affect the Activity of the Bebtelovimab Antibody.

Journal of chemical information and modeling·2026

Related Experiment Video

Updated: Sep 27, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K

Ultra-deep sequencing data from a liquid biopsy proficiency study demonstrating analytic validity.

Binsheng Gong1, Ira W Deveson2,3, Timothy Mercer4,5

  • 1Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, 72079, USA.

Scientific Data
|April 14, 2022
PubMed
Summary
This summary is machine-generated.

This study evaluated circulating tumor DNA (ctDNA) assays, crucial for precision oncology. The comprehensive dataset reveals insights into ctDNA sequencing technology, aiding clinical utility assessment.

More Related Videos

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
05:26

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

4.1K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.9K

Related Experiment Videos

Last Updated: Sep 27, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
05:26

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

4.1K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.9K

Area of Science:

  • Molecular Biology
  • Genomics
  • Oncology

Background:

  • Circulating tumor DNA (ctDNA) assays are increasingly vital in precision oncology.
  • Understanding the analytical validity and technical limitations of ctDNA sequencing is critical due to its rapid adoption.
  • Previous work established accuracy and reproducibility benchmarks for ctDNA assays.

Purpose of the Study:

  • To evaluate the analytical performance of five industry-leading ctDNA assays.
  • To assess ctDNA sequencing across multiple platforms and clinical sites.
  • To generate a comprehensive dataset for understanding ultra-deep ctDNA sequencing technology.

Main Methods:

  • A multi-site, cross-platform study design was employed.
  • Tailor-made reference samples with varying DNA input levels were utilized.
  • Data were collected from 12 participating clinical and research facilities.

Main Results:

  • The study assessed ctDNA sequencing performance across diverse mutation frequencies and sequencing coverage depths.
  • A comprehensive dataset was generated, encompassing multiple key variables.
  • Valuable insights into ultra-deep ctDNA sequencing technology were obtained.

Conclusions:

  • The generated dataset is the most comprehensive public-facing resource of its kind.
  • This proficiency study and dataset are essential steps towards establishing clinical utility for ctDNA assays.
  • Further validation is needed to fully realize the potential of ctDNA assays in clinical practice.